Australia's LTR Pharma gains most in nearly 2 years on positive FDA drug trial

Ltr Pharma

01/05/2026 04:16

** Shares of Australia's LTR Pharma LTP.AX rise as much as 55.6% to A$0.630, biggest intraday pct gain since June 7, 2024

** Stock touches its highest level since January 22

     ** Biopharma company releases interim phase II study results for its erectile dysfunction drug SPONTAN

** Co says data supports the U.S. Food and Drug Administration's (FDA) approval pathway, and statistical analysis to be finalised

** Expects full results by Q326

** Stock up 32.1% so far this week, set for its best week since mid-August 2025, if gains hold

** Despite moves, stock down 28.5%

(Reporting by Aamir Sheik Khalid in Bengaluru)

((Aamir.SheikKhalid@thomsonreuters.com))